[Biological disease-modifying anti-rheumatic drugs for pregnant and lactating women or male partners].
Ugeskr Laeger
; 183(8)2021 02 22.
Article
em Da
| MEDLINE
| ID: mdl-33660603
ABSTRACT
Effective medical treatment of rheumatic diseases during pregnancy and lactation is important, but the evidence for use of biological disease-modifying anti-rheumatic drugs (bDMARDs) is sparse and recommendations conflicting, which we discuss in this review. While some tumour necrosis factor (TNF)-α inhibitors appear safe during pregnancy and lactation, the evidence for use of non-TNF-α inhibitors is still too sparse to exclude adverse pregnancy outcomes and harm to the lactating child. The limited evidence on paternal exposure indicates, that TNF-α inhibitors do not affect male fertility or harm offspring. For non-TNF-α inhibitors, the evidence is still insufficient to draw any conclusion.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Doenças Reumáticas
/
Antirreumáticos
Tipo de estudo:
Guideline
Limite:
Child
/
Female
/
Humans
/
Male
/
Pregnancy
Idioma:
Da
Revista:
Ugeskr Laeger
Ano de publicação:
2021
Tipo de documento:
Article